Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity

INTRODUCTION: The inhibition of estrogen receptor (ER) α action with the ER antagonist tamoxifen is an established treatment in the majority of breast cancers. De novo or acquired resistance to this therapy is common. Expression of ERβ in breast tumors has been implicated as an indicator of tamoxife...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindberg, Karolina, Helguero, Luisa A, Omoto, Yoko, Gustafsson, Jan-Åke, Haldosén, Lars-Arne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219206/
https://www.ncbi.nlm.nih.gov/pubmed/21492444
http://dx.doi.org/10.1186/bcr2865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219206/
https://www.ncbi.nlm.nih.gov/pubmed/21492444
http://dx.doi.org/10.1186/bcr2865

Ejemplares similares